Fig. 5

In vitro validation of MEOX2 expression levels and function. (A) MEOX2 expression levels in different cell lines based on the HPA database. (B) The sensitivity of IOSE-80, A2780, and A2780-DDP cells to cisplatin was evaluated using the CCK-8 assay, and IC50 values were calculated for comparison. (C) MEOX2 protein expression in IOSE-80, A2780, and A2780-DDP cells was evaluated by Western blot analysis. (D) The relative mRNA expression levels of MEOX2 in A2780 and A2780-DDP cells were determined by qPCR, normalized to the expression levels in IOSE-80 cells. (E-F) The knockdown efficiency of MEOX2 in A2780-DDP cells was validated by qPCR (E) and Western blot (F), showing changes in mRNA and protein expression. (G) The impact of MEOX2 knockdown on cisplatin sensitivity in A2780-DDP cells was evaluated, as reflected by changes in IC50 values. (H) Cell viability was measured in different groups treated with 5 μM cisplatin (DDP) or untreated (NC), normalized to the viability of IOSE-80 cells. The inset graph illustrates the effects of cisplatin treatment on cell viability, excluding interference from initial viability differences among groups. (I) Apoptosis rates in different cell groups were analyzed using flow cytometry after cisplatin treatment, including total apoptosis (All apoptosis), early apoptosis (Early apoptosis), and late apoptosis (Late apoptosis). (J) The effect of MEOX2 knockdown on the migratory ability of A2780-DDP cells was assessed using a wound healing assay, comparing migration distances at 0 h and 24 h (scale bar = 100 μm; labelled as a red line). All experiments were performed in triplicate, and data are presented as mean ± standard deviation (Mean ± SD). For statistical annotations in Figures H and I, Greek letters (α, β, γ, δ) of the same color represent the groups being compared, with different letters indicating statistically significant differences between groups